Liver Biomarkers in Anorexia Nervosa

Recruiting

• Conditions: Anorexia Nervosa
• Interventions: Diagnostic Test: Fibroscan

• Registration Number: NCT05861375
• Lead Sponsor: Nantes University Hospital

Brief Summary

The main goal of the Liver Biomarkers in Anorexia Nervosa (LIBAN) study is to determine the prevalence of liver fibrosis in patient with Anorexia Nervosa.

Detailed Description

Prevalence of hepatic fibrosis will be non-invasively investigated, in the Anorexia Nervosa inpatient population, using the Fibroscan ®. Furthermore, liver blood markers will be assessed.

Study Timeline

• Study First Submitted: 2023-02-07
• Study First Submitted QC: 2023-05-12
• Study First Posted: 2023-05-16
• Study Start: 2023-06-23
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-12
• Last Update Posted: 2024-01-17
• Primary Completion: 2025-04-30
• Study Completion: 2025-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Non applicable (NA)	Fibroscan	Patients with Anorexia Nervosa hospitalized for malnutrition

Primary Outcome Measures

Name	Time	Method
Liver fibrosis prevalence in patients with Anorexia nervosa	Day one	Liver stiffness will be assessed using Fibroscan (kPA) within the 24 hours following admission to the endocrinology, diabetology and nutrition department.

Trial Locations

Locations (1)

Nantes University Hospital; 🇫🇷 Nantes, Loire-Atlantique, France